TadalafilThird Party Manufacturing in India

Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5, the predominant PDE isoenzyme responsible for the hydrolysis of cGMP in the corpus cavernosum of the penis and in pulmonary arterial smooth muscle. Under normal physiological conditions, sexual stimulation or nitric oxide donor compounds trigger the release of nitric oxide from non-adrenergic non-cholinergic nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide diffuses into vascular smooth muscle cells and activates soluble guanylate cyclase, which catalyses the conversion of guanosine triphosphate to intracellular cGMP. Elevated cGMP levels activate protein kinase G, which phosphorylates multiple downstream targets including calcium-sensitive potassium channels, inositol trisphosphate receptors, and phospholamban, resulting in decreased intracellular calcium concentration, smooth muscle relaxation, increased arterial blood flow into the corpus cavernosum, and penile erection. Tadalafil potentiates this natural nitric oxide-cGMP signalling cascade by preventing the degradation of cGMP by PDE5, thereby amplifying and prolonging the erectile response. Unlike other PDE5 inhibitors, tadalafil exhibits a slower dissociation rate from the PDE5 active site, resulting in a significantly longer half-life of approximately 17.5 hours that supports once-daily dosing and provides up to 36 hours of therapeutic efficacy. Tadalafil is highly selective for PDE5 relative to other PDE isoenzymes, with 10,000-fold selectivity over PDE1 through PDE4 and 700-fold selectivity over PDE6.

Therapeutic Uses

Tadalafil is prescribed for the treatment of:

• Erectile Dysfunction: Tadalafil is indicated for the treatment of erectile dysfunction in adult men, available as both on-demand 20 mg dosing and once-daily 5 mg dosing for continuous readiness.
• Benign Prostatic Hyperplasia: Tadalafil 5 mg once daily is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia in men with or without erectile dysfunction, improving urinary flow and reducing lower urinary tract symptoms.
• Pulmonary Arterial Hypertension: Tadalafil is indicated as 20 mg and 40 mg tablets for the treatment of pulmonary arterial hypertension in WHO Functional Class II and III patients, improving exercise capacity and delaying clinical worsening.
• Erectile Dysfunction with BPH: Tadalafil is uniquely indicated for the concurrent treatment of both erectile dysfunction and benign prostatic hyperplasia in men presenting with both conditions, allowing a single daily tablet to address two urological complaints.

Why Manufacturers Choose Tadalafil

Tadalafil is the leading PDE5 inhibitor molecule globally, offering distinct pharmacokinetic advantages over sildenafil and vardenafil through its longer duration of action, lower food interaction, and once-daily dosing indication for both ED and BPH. Available in 5 mg, 10 mg, 20 mg, 50 mg, and 100 mg tablet strengths, the product serves both on-demand and chronic daily dosing segments across urology and cardiology channels. Indian manufacturers benefit from tadalafil's inclusion in multiple therapeutic categories, expanding the addressable prescriber base from urologists to cardiologists, primary care physicians, and pulmonologists for the PAH indication. The established API supply chain, well-characterised formulation technology, and strong demand in both domestic branded and export generic markets make tadalafil a high-volume product with favourable margins. The molecule's patent expiry in regulated markets has opened substantial generic opportunities. This makes Tadalafil one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.